Healthcare
Live Price
Offline$8.55
-10.15% today
1Y Change
-38.84%
Window
Jun 25, 2025 → Jun 17, 2026
Coverage: 246 bars · Jun 25, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Ambu A/S (AMBBY) is a Healthcare stock with a market cap of $17.79B and listed on OTC. The stock last traded around $8.54 and down 38.8% across the available one-year price window (Jun 25, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +5.5%, EPS growth of +144.3%, a dividend yield of 0.6%. What stands out right now is revenue +5.5%, EPS +144.3%, free cash flow +21.2% with operating margin 11.6% and ROIC 8.7%. The dividend is present but secondary, with a yield around 0.6%. Valuation already assumes a fairly strong business story at P/E 32.9 and price/sales 2.9. Stock Foundry combines AMBBY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
AMBBY
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
AMBBY Max Drawdown
-43.33%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for AMBBY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$4.0B
-9.7% YoY
FY Net Income
$247.0M
+165.6% YoY
Free Cash Flow
-$256.0M
+44.7% YoY
Revenue Growth
+5.5%
EPS Growth
+144.3%
Gross Margin
55.9%
Net Margin
8.9%
Income statement
DKK
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 5.7B | 5.4B | 4.8B | 4.4B | 4.0B |
| Gross Profit | 3.2B | 3.2B | 2.7B | 2.6B | 2.5B |
| Operating Income | 738M | 645M | 302M | 144M | 340M |
| EBITDA | 1.1B | 682M | 644M | 492M | 500M |
| Net Income | 574M | 235M | 168M | 93M | 247M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
DKK
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 868M | 615M | 157M | 187M | 64M |
| Total Assets | 7.7B | 7.2B | 6.9B | 7.2B | 5.7B |
| Total Liabilities | 1.6B | 1.6B | 1.5B | 3.0B | 1.8B |
| Shareholder Equity | 6.0B | 5.6B | 5.4B | 4.3B | 4.0B |
| Total Debt | 548M | 558M | 584M | 1.8B | 823M |
| Net Debt | -320M | -57M | 427M | 1.7B | 759M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
328M
+245.3% YoY
Capital Expenditures
584M
-4.7% YoY
Free Cash Flow
256M
+44.7% YoY
Key ratios
Gross Margin
55.9%
Operating Margin
11.6%
Net Margin
8.9%
ROE
9.1%
Debt / Equity
0.17x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.